aurograb + vancomycin

Aurograb + vancomycin is a **combination antibacterial therapy** composed of two distinct agents: **aurograb**, an antibacterial protein derived from the bacteriophage-derived protein (specifically, the phage protein gp053), and **vancomycin**, a glycopeptide antibiotic. The combination is under investigation for its potential synergistic activity against **methicillin-resistant Staphylococcus aureus (MRSA)** and other Gram-positive infections. - **Aurograb** acts by binding to bacterial ribosomes, inhibiting protein synthesis and disrupting cell metabolism. Its interaction potentially sensitizes bacteria to other antibiotics[10]. - **Vancomycin** inhibits bacterial cell wall synthesis by binding firmly to the D-alanyl-D-alanine terminus of cell wall precursor units, thereby blocking the peptidoglycan polymerization essential for bacterial viability[6]. This combination is primarily indicated in preclinical/experimental settings to overcome resistance mechanisms and enhance efficacy in difficult-to-treat MRSA or biofilm-related infections.

Other names

aurograb + vancomycin